<sup>18</sup>F-FDG PET/CT显像在多发性骨髓瘤诊疗中的研究进展

李亚男; 董华; 李亚男; 董华

doi:10.3760/cma.j.cn121381-201912031-00017

[1]

Lu J, Lu J, Chen W, et al. Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis[J/OL]. Blood Cancer J, 2014, 4(8): e239[2019-12-24]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219472. DOI: 10.1038/bcj.2014.55.

[2]

中国医师协会血液科医师分会, 中华医学会血液学分会, 中国医师协会多发性骨髓瘤专业委员会. 中国多发性骨髓瘤诊治指南(2017年修订)[J]. 中华内科杂志, 2017, 56(11): 866-870. doi: 10.3760/cma.j.issn.0578-1426.2017.11.021
Hematology Physician Branch of Chinese Medical Doctor Association, Hematology Society of Chinese Medical Association, Multiple Myeloma Professional Committee of Chinese Medical Doctor Association. The guidelines for the diagnosis and management of multiple myeloma in China (2017 revision)[J]. Chin J Intern MedChin J Intern Med, 2017, 56(11): 866-870. doi: 10.3760/cma.j.issn.0578-1426.2017.11.021

[3]

Pianko MJ, Terpos E, Roodman GD, et al. Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease[J]. Clin Cancer ResClin Cancer Res, 2014, 20(23): 5888-5897. doi: 10.1158/1078-0432.CCR-14-1692

[4]

中华医学会血液学分会. 多发性骨髓瘤骨病诊治指南[J]. 中华血液学杂志, 2011, 32(10): 721-723. doi: 10.3760/cma.j.issn.0253-2727.2011.10.023
Hematology Society of Chinese Medical Association. Guidelines for the diagnosis and treatment of multiple myeloma bone disease[J]. Chin J HematolChin J Hematol, 2011, 32(10): 721-723. doi: 10.3760/cma.j.issn.0253-2727.2011.10.023

[5]

Zamagni E, Tacchetti P, Cavo M. Imaging in multiple myeloma: how? When?[J]. BloodBlood, 2019, 133(7): 644-651. doi: 10.1182/blood-2018-08-825356

[6]

姚树展, 孟繁禄, 刘松涛, 等. PET/CT对多发性骨髓瘤的诊断价值[J]. 中华核医学杂志, 2009, 29(2): 82-84. doi: 10.3760/cma.j.issn.0253-9780.2009.02.003
Yao SZ, Meng FL, Liu ST, et al. The staging value with PET/CT imaging in multiple myeloma[J]. Chin J Nucl MedChin J Nucl Med, 2009, 29(2): 82-84. doi: 10.3760/cma.j.issn.0253-9780.2009.02.003

[7]

Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma[J]. Lancet OncolLancet Oncol, 2014, 15(12): e538-e548. doi: 10.1016/S1470-2045(14)70442-5

[8]

Cavo M, Terpos E, Nanni C, et al. Role of ¹⁸F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group[J]. Lancet OncolLancet Oncol, 2017, 18(4): e206-e217. doi: 10.1016/S1470-2045(17)30189-4

[9]

Takahashi MES, Mosci C, Souza EM, et al. Proposal for a quantitative ¹⁸F-FDG PET/CT metabolic parameter to assess the intensity of bone involvement in multiple myeloma[J/OL]. Sci Rep, 2019, 9(1): 16429[2019-12-24]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848137. DOI: 10.1038/s41598-019-52740-2.

[10]

Li Y, Liu JR, Huang BH, et al. Application of PET/CT in treatment response evaluation and recurrence prediction in patients with newly-diagnosed multiple myeloma[J/OL]. Oncotarget, 2017, 8(15): 25637−25649[2019-12-24]. https://www.oncotarget.com/article/11418/text. DOI: 10.18632/oncotarget.11418.

[11]

宋烈晶, 徐海青, 陆克义, 等. ¹⁸F-FDG和⁹⁹Tc^m-MDP显像诊断多发性骨髓瘤骨病的对比研究[J]. 国际放射医学核医学杂志, 2019, 43(4): 303-307. doi: 10.3760/cma.j.issn.1673-4114.2019.04.002
Song LJ, Xu HQ, Lu KY, et al. Comparative study of ¹⁸F-FDG PET/CT and ⁹⁹Tc^m-MDP whole body bone scan for multiple myeloma bone disease detection[J]. Int Radiat Med Nucl MedInt Radiat Med Nucl Med, 2019, 43(4): 303-307. doi: 10.3760/cma.j.issn.1673-4114.2019.04.002

[12]

Moreau P, Attal M, Caillot D, et al. Prospective evaluation of magnetic resonance imaging and [¹⁸F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study[J]. J Clin OncolJ Clin Oncol, 2017, 35(25): 2911-2918. doi: 10.1200/JCO.2017.72.2975

[13]

Jung SH, Kwon SY, Min JJ, et al. ¹⁸F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage Ⅱ and Ⅲ with the revised international staging system[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2019, 46(1): 107-115. doi: 10.1007/s00259-018-4114-0

[14]

Aljama MA, Sidiqi MH, Buadi FK, et al. Utility and prognostic value of ¹⁸F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma[J]. Am J HematolAm J Hematol, 2018, 93(12): 1518-1523. doi: 10.1002/ajh.25279

[15]

Moon SH, Choi WH, Yoo IR, et al. Prognostic value of baseline ¹⁸F-fluorodeoxyglucose PET/CT in patients with multiple myeloma: a multicenter cohort study[J]. Korean J RadiolKorean J Radiol, 2018, 19(3): 481-488. doi: 10.3348/kjr.2018.19.3.481

[16]

Matsue K, Kobayashi H, Matsue Y, et al. Prognostic significance of bone marrow abnormalities in the appendicular skeleton of patients with multiple myeloma[J]. Blood AdvBlood Adv, 2018, 2(9): 1032-1039. doi: 10.1182/bloodadvances.2017014720

[17]

Abe Y, Narita K, Kobayashi H, et al. Medullary abnormalities in appendicular skeletons detected with ¹⁸F-FDG PET/CT predict an unfavorable prognosis in newly diagnosed multiple myeloma patients with high-risk factors[J]. AJR Am J RoentgenolAJR Am J Roentgenol, 2019, 213(4): 918-924. doi: 10.2214/AJR.19.21283

[18]

Li CY, Shao FQ, Yang YH, et al. Diffuse infiltration of multiple myeloma with initial manifestation of cavernous sinus syndrome unveiled by ¹⁸F-FDG PET/CT[J]. Clin Nucl MedClin Nucl Med, 2019, 44(9): 746-747. doi: 10.1097/RLU.0000000000002722

[19]

Velaga J, Liang HH, Gopalakrishnan SK. Multiple myeloma of testes and spermatic cord on ¹⁸F-FDG PET/CT[J]. Clin Nucl MedClin Nucl Med, 2019, 44(4): 297-298. doi: 10.1097/RLU.0000000000002462

[20]

Khan AM, Azar I, Najjar S, et al. A case of aggressive multiple myeloma with extramedullary involvement of the female reproductive system, thyroid and breasts[J/OL]. Case Rep Hematol, 2019, 2019: article ID 7348504[2019-12-24]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701299. DOI: 10.1155/2019/7348504.

[21]

Bailly C, Carlier T, Jamet B, et al. Interim PET analysis in first-line therapy of multiple myeloma: prognostic value of ΔSUV_maxin the FDG-avid patients of the IMAJEM study[J]. Clin Cancer ResClin Cancer Res, 2018, 24(21): 5219-5224. doi: 10.1158/1078-0432.CCR-18-0741

[22]

夏冰, 吴凌, 李梦真, 等. ¹⁸F-FDG PET-CT显像特征在初诊多发性骨髓瘤患者预后评估中的价值[J]. 白血病·淋巴瘤, 2019, 28(8): 457-462. doi: 10.3760/cma.j.issn.1009-9921.2019.08.002
Xia B, Wu L, Li MZ, et al. Value of ¹⁸F-FDG PET-CT imaging features in the prognosis evaluation of newly diagnosed patients with multiple myeloma[J]. J Leukemia & LymphomaJ Leukemia & Lymphoma, 2019, 28(8): 457-462. doi: 10.3760/cma.j.issn.1009-9921.2019.08.002

[23]

Abe Y, Narita K, Kobayashi H, et al. Pretreatment ¹⁸F-FDG PET/CT combined with quantification of clonal circulating plasma cells as a potential risk model in patients with newly diagnosed multiple myeloma[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2019, 46(6): 1325-1333. doi: 10.1007/s00259-019-4275-5

[24]

Abe Y, Ikeda S, Kitadate A, et al. Low hexokinase-2 expression-associated false-negative ¹⁸F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2019, 46(6): 1345-1350. doi: 10.1007/s00259-019-04312-9

[25]

Ormond Filho AG, Carneiro BC, Pastore D, et al. Whole-body imaging of multiple myeloma: diagnostic criteria[J]. RadiographicsRadiographics, 2019, 39(4): 1077-1097. doi: 10.1148/rg.2019180096

[26]

Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma[J]. Lancet OncolLancet Oncol, 2016, 17(8): e328-e346. doi: 10.1016/S1470-2045(16)30206-6

[27]

Dammacco F, Rubini G, Ferrari C, et al. ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders[J]. Clin Exp MedClin Exp Med, 2015, 15(1): 1-18. doi: 10.1007/s10238-014-0308-3

[28]

Stolzenburg A, Lückerath K, Samnick S, et al. Prognostic value of [¹⁸F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2018, 45(10): 1694-1704. doi: 10.1007/s00259-018-3997-0

[29]

Ripani D, Caldarella C, Za T, et al. Prognostic significance of normalized FDG-PET parameters in patients with multiple myeloma undergoing induction chemotherapy and autologous hematopoietic stem cell transplantation: a retrospective single-center evaluation[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2019, 46(1): 116-128. doi: 10.1007/s00259-018-4108-y

[30]

Morvan L, Carlier T, Jamet B, et al. Leveraging RSF and PET images for prognosis of multiple myeloma at diagnosis[J]. Int J Comput Assist Radiol SurgInt J Comput Assist Radiol Surg, 2020, 15(1): 129-139. doi: 10.1007/s11548-019-02015-y

[31]

Nanni C, Zamagni E, Versari A, et al. Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian myeloma criteria for PET use)[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2016, 43(3): 414-421. doi: 10.1007/s00259-015-3200-9

[32]

Nanni C, Versari A, Chauvie S, et al. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET use)[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2018, 45(5): 712-719. doi: 10.1007/s00259-017-3909-8

[33]

Bhatnagar V, Wu Y, Goloubeva OG, et al. Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center study[J]. CancerCancer, 2015, 121(7): 1064-1070. doi: 10.1002/cncr.29160